NewsEvents

Your Yourlocation: Home > Efficacy and safety evaluation of tiotropium bromide(136310-93-5) inhalation agent on stable moderate to severe COPD

To investigate the clinical efficacy and safety of tiotropium bromide(136310-93-5) inhaler in the treatment of moderate to severe COPD stable phase.

Methods: 126 patients with moderate to severe COPD were randomly divided into experimental group and control group. The patients in the experimental group were treated with tiotropium bromide(136310-93-5) inhalation. The control group was treated with ipratropium bromide aerosol, before and after treatment, the clinical symptom scores of the two groups were compared, 6 minD distance(6MWD), pulmonary function test, arterial blood gas analysis, the incidence of adverse reactions were recorded during the treatment.

Results: The FEV1 /FVC, PaO2 and 6MWD of the experimental group were significantly higher than those of the control group(P <0.05). The symptom score and PaCO2 were significantly lower than those in the control group(P <0.05). Control group(P <0.05), no serious adverse reactions occurred in both groups. Conclusion: Tiotropium bromide(136310-93-5) is effective and safe for moderate and severe COPD in stable period.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved